

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA HEALTH GROUP INC.

中國醫療集團有限公司

(Carrying on business in Hong Kong as “萬全醫療集團”)
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 08225)

Voluntary announcement

New development for the Group's business in the post-COVID-19 era

INSPO Aishen, a global social software that cares for elderly dementia patients, won the 2023 Canadian National Youth Innovation Competition Award on May 18th at the National Art Center in Ottawa and was awarded the Governor's Fund RHF established by Queen Elizabeth. This software was developed by Alan G, a CHG AI medical development colleague based on the campus of Stanford University from China Health Group (CHG). Thanks to the guidance and encouragement of Nobel laureate American academician neuroscience expert Thomas C. Südhof, INSPO Aishen will soon be launched simultaneously in China, helping nearly 20 million dementia families.

The Group's Xi'en Clinical Center for the Prevention and Treatment of Dementia and Stroke is a leading research center in this field in China, which has conducted and completed more than ten clinical studies on dementia and stroke area. The global award of INSPO will greatly assist the group in conducting research on cognitive impairment, the most challenging human disease, and stroke, the first fatal disease in China, overseas, creating value for shareholders.

China Health Group is a leading digital healthcare service provider in the areas of new drug development innovation, research-based specialty clinics and research-based product promotion driven by real-world clinical research and medical big data. The Group focuses on major disease areas such as brain science and allergic reactions, and has built five major specialty brands: Baimin anti-allergic, Xixin spirit, Xien preventing stroke dementia, Yueting quitting Smoking Addiction and Rare Disease ALS.

The management of the group believes that the medical service field, especially the brain science (psychiatric and CNS field), has experienced explosive growth in the post pandemic era, which will bring sustained and good development to the enterprise. Therefore, it is hereby announced. Due to the huge uncertainty of the market, please consult professionals to invest cautiously.

By order of the Board
China Health Group Inc.
GUO Xia
Chairman

Hong Kong, 21 May 2023

As at the date hereof, the Board comprises two executive Directors, being Mr. GUO Xia and Dr. SONG Xuemei; one non-executive Director, being Mr. SU Yi; and three independent non-executive Directors, being Mr. QIU Rui, Dr. NI Binhui and Mr. ZHEN Ling. This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading. This announcement will remain on the "Latest Listed Company Information" page of the GEM website at <http://www.hkgem.com> for 7 days from the date of its posting. This announcement will also be posted on the Company's website at <http://www.chgi.net>.